ThyroSeq is specifically designed for thyroid nodules when other clinical tools are unable to confidently say whether your thyroid nodule is benign or malignant and to guide personalized management if you do have cancer.
Approximately 20% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate by cytology, making diagnosis of the nodule unclear. ThyroSeq provides clear results to help determine if your nodule is likely benign or malignant.
ThyroSeq testing can safely prevent unnecessary diagnostic surgery in the majority of patients with thyroid nodules with indeterminate (Bethesda III or IV) cytology. When ThyroSeq results are negative for these nodules, the probability of cancer is similar to that of a benign cytology diagnosis.
ThyroSeq provides prognostic information about cancer
If ThyroSeq results are positive, the test provides additional information about the nodule to help you and your doctor decide your individualized plan, which in some cases may include preserving part of your thyroid and protecting your natural thyroid function.